“Hanmi Pharmaceutical’s Next-Generation Obesity Drug Named Zantrutide.”
3 sources: ajupress.com, chosun.com, hanmi.co.kr. Hanmi Pharmaceutical announced that the WHO assigned zantrutide as the international nonproprietary name for its obesity-drug candidate HM15275. It remains in clinical trials; the name assignment is not regulatory approval.
checked on the web by Perplexity
“체중 25% 이상 감량 + 근 손실 최소화” 비만 신약, 국제 일반명 등재 | 한미약품HM15275 | 파이프라인 | 한미약품
R&D Management | 2025-26 Hanmi Pharm ESG Report